

	Break or Meal Function
	Industry Session
	Partner Session or Symposium
	ACTRIMS Invited Session
	Poster or Discussion Session

THURSDAY, FEBRUARY 29	
7:30 - 9:00 AM	Breakfast
8:00 - 9:00 AM	SS1. Industry Supported CE Satellite Symposium 1
9:00 - 9:15 AM	Break
9:15 - 10:15 AM	Welcome & Kenneth P. Johnson Memorial Lecture
	Anne Cross, <i>Washington University in St. Louis</i> <i>Pioneering B-Cell Therapies</i>
10:15 - 10:30 AM	Break
10:30 - 12:05 PM	S1. Session 1 – Emerging Concepts in MS
Theme: Highlighting studies that inform our understanding of the pathogenic mechanisms in MS, introduce novel measures to capture disease activity and advance treatment options for affected individuals. <i>This session will be comprised of platform presentations by Young Investigators selected from submitted abstracts. Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.</i> Chairs: Jiwon Oh, <i>University of Toronto</i> Benjamin Segal, <i>The Ohio State University</i>	
	S1.1 - S1.6 <i>Presentations selected from submitted abstracts.</i>
12:05 - 1:30 PM	Lunch in the Hub
12:20 - 1:20 PM	SS2. Industry Supported CE Satellite Symposium 2
12:30 - 1:15 PM	Brain Exchange 1: Gender Parity in Career Progression
	Brain Exchange 2: Barriers to Personalized Medicine
1:30 - 2:30 PM	AP1. LACTRIMS Symposium - Bringing Down the Walls in Multiple Sclerosis
Chairs: Fernando Gracia, <i>LACTRIMS President, Hospital Santo Tomás, Universidad Interamericana de Panamá</i> and Carlos Navas, <i>Clinica Universitaria Colsanitas - Hospital San Jose</i>	
1:30 – 1:35	Introduction
1:35 – 1:50	AP1.1 Setting the Agenda for MS Research in Latin America Results from a Delphi Consensus Juan Ignacio Rojas, <i>Hospital Universitario de CEMIC</i>
1:50 – 2:05	AP1.2 Big Data Research in MS in LATAM: Future Prospects and Gaps Jefferson Becker, <i>Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)</i>
2:05 – 2:20	AP1.3 Breaking Down Race and Ethnicity in MS Across LATAM Teresa Corona, <i>Universidad Nacional Autónoma de México</i>
2:20 – 2:30	Q & A
2:30 - 2:45 PM	Break

Thursday, February 29th Continued

2:45 - 4:15 PM	S2. Session 2 - MS Across Populations and Access to Care
Theme: The session will focus on barriers to equitable research, care delivery, and the interplay of genetics and social determinants of health in multiple sclerosis. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i>	
Chairs: Dalia Rotstein, <i>University of Toronto</i> Kathleen Munger, <i>MultiCare Neuroscience & Sleep Medicine</i>	
2:45 - 2:50	Introduction
2:50 - 3:05	S2.1 Barriers to Research, Sharing Data, and Privacy Data Viviane Poupon, <i>Brain Canada</i>
3:05 - 3:20	S2.2 Improving Access to MS Care Through Technology Marisa McGinley, <i>Cleveland Clinic</i>
3:20 - 3:35	S2.3 Debate: Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics (YES) Philip De Jager, <i>Columbia University</i>
3:35 - 3:50	S2.4 Debate: Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics (NO) Annette Langer-Gould, <i>Kaiser Permanente</i>
3:50 - 4:15	Q & A
4:15 - 4:30 PM	Break
4:30 - 5:35 PM	CE1. Cutting Edge Developments
Theme: Cutting-edge platform presentations selected from submitted abstracts. <i>Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.</i>	
Chairs: Scott Zamvil, <i>University of California - San Francisco</i> Shannon Dunn, <i>University of Toronto</i>	
	CE1.1 – CE 1.4 <i>Presentations selected from submitted abstracts</i>
5:35 - 6:00 PM	Cocktail Break in the Hub
6:00 - 7:30 PM	Poster Session 1
7:45 - 9:00 PM	iWiMS Event

FRIDAY, MARCH 1

7:30 - 9:00 AM	Breakfast
8:00 - 9:00 AM	SS3. Industry Supported CE Satellite Symposium 3
9:00 - 9:15 AM	Break
9:15 - 10:45 AM	S3. Session 3 – CNS Barriers Thinking Outside the Box
Theme: Exploring CNS barriers and their associated cells outside the traditional model of the blood brain barrier. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i> Chairs: Stephanie Zandee, <i>Université de Montréal</i> Jessica Williams, <i>Cleveland Clinic</i>	
9:15 – 9:20	Introduction
9:20 - 9:35	S3.1 Ependymal Cells and Their Role in CNS Inflammation Jo Anne Stratton, <i>McGill University</i>
9:35 - 9:50	S3.2 Choroid Plexus as Route of CNS Inflammation Maria Lehtinen, <i>Boston Children's Hospital, Harvard Medical School</i>
9:50 - 10:05	S3.3 Imaging the Choroid Plexus Niels Bergsland, <i>University at Buffalo</i>
10:05 – 10:20	S3.4 Vascular Immunity Dimitrios Davalos, <i>Cleveland Clinic</i>
10:20 – 10:45	Q & A
10:45 - 11:00 AM	Break
11:00 AM - 12:05 PM	CE2. Cutting Edge Developments
Theme: Cutting-edge platform presentations selected from submitted abstracts. <i>Each presenter will have 15 minutes total for their presentation – 12 minutes for the presentation and 3 minutes for Q&A.</i> Chairs: Kevin O'Connor, <i>Yale University</i> Carlos Camara-Lemarroy, <i>University of Calgary</i>	
	CE2.1 – CE2.4 <i>Presentations selected from submitted abstracts</i>
12:05 - 1:30 PM	Lunch in the Hub
12:20 - 1:20 PM	SS4. Industry Supported CE Satellite Symposium 4
12:30 - 1:15 PM	Brain Exchange 3: Barriers to Imaging Myelin
	Brain Exchange 4: Differential Diagnosis: Barriers and Challenges
1:30 - 2:30 PM	AP2. European Charcot Foundation Symposium - Moving the Patient at the Center
Chairs: TBD	
1:30 – 1:35	Introduction
1:35 – 1:50	AP2.1 PROs, From Clinical Trials to Clinical Practice and Vice-Versa: Lesson Learnt from Global PROMS Initiative Paola Zaratini, <i>Italian MS Society & Foundation</i>
1:50 – 2:05	AP2.2 Are the Wearable Devices Mature to Monitor MS? Letizia Leocani, <i>Vita-Salute San Raffaele University</i>
2:05 – 2:20	AP2.3 PROs in MS Registries and Clinical Care Robert McBurney, <i>Accelerated Cure Project for Multiple Sclerosis</i>
2:20 – 2:30	Q & A

Friday, March 1st Continued

2:30 - 2:45 PM	Break
2:45 - 4:15 PM	S4. Session 4 – Barriers to Neural Repair
Theme: Basic and clinical topics on barriers to, and proposed solutions for, remyelination. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i> Chairs: Jason Plemel, <i>University of Alberta</i> Veronique Miron, <i>University of Toronto</i>	
2:45 – 2:50	Introduction
2:50 - 3:05	S4.1 Next Generation Animal Models for Studying Remyelination in MS Jennifer Orthmann - Murphy, <i>University of Pennsylvania</i>
3:05 - 3:20	S4.2 Engineering 3D Platforms to Overcome Barriers of Drug Discovery for MS Krystyn Van Vliet, <i>Cornell University</i>
3:20 - 3:35	S4.3 Immune Barriers to Remyelination Jeffrey Huang, <i>Georgetown University</i>
3:35 - 3:50	S4.4 Barriers in Remyelination Trials Siddharthan Chandran, <i>University of Edinburgh</i>
3:50 - 4:15	Q & A
4:15 - 4:30 PM	Break
4:30 - 5:30 PM	BP1. NMSS Barancik Award Presentation and Talk
5:30 - 6:00 PM	Cocktail Break in the Hub
6:00 - 7:30 PM	Poster Session 2
SATURDAY, MARCH 2	
7:30 - 9:00 AM	Breakfast
8:00 - 9:30 AM	AP3. Joint NAIMS & IMSVISUAL Symposium: Vascular/Metabolic/Advanced Imaging Using Portable Platforms
Chairs: NAIMS: Joel Stein, <i>University of Pennsylvania</i> and Shannon Kolind, <i>University of British Columbia</i> IMSVISUAL: Ahmed Toosy, <i>University College London</i> and Angela Vidal-Jordana, <i>Multiple Sclerosis Centre of Catalonia-Vall d'Hebron University Hospital</i>	
8:00 – 8:05	Introduction
8:05 – 8:25	AP3.1 Adaptive Optics in MS Daniel Harrison, <i>University of Maryland</i>
8:25 – 8:45	AP3.2 Portable MRI for Multiple Sclerosis Joel Stein, <i>University of Pennsylvania</i>
8:45 – 9:30	<i>Presentations selected from submitted abstracts</i>
9:30 - 9:45 AM	Break

Saturday, March 2nd Continued

9:45 - 11:15 AM	S5. Session 5 – Rehabilitation Without Borders
Theme: Examine the mechanisms of rehabilitation and how to further rehabilitation trials. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i> Chairs: Kathy Zackowski, <i>National MS Society</i> Gabrielle Macaron, <i>Université de Montréal</i>	
9:45 - 9:50	Introduction
9:50 - 10:05	S5.1 Exercise as a Therapeutic Intervention in Multiple Sclerosis Lara Pilutti, <i>University of Ottawa</i>
10:05 - 10:20	S5.2 Basic Mechanisms That May Underpin Repair/Rehabilitation Don Mahad, <i>University of Edinburgh</i>
10:20 - 10:35	S5.3 Cognitive Rehabilitation in Multiple Sclerosis: What Has Been Achieved? Nancy Chiaravalloti, <i>Kessler Foundation</i>
10:35 - 10:50	S5.4 Rehabilitation Clinical Trials: Barriers and Unmet Needs Robert Motl, <i>University of Illinois at Chicago</i>
10:50 - 11:15	Q & A
11:15 - 11:30 AM	Break
11:30 AM - 12:15 PM	LB1: Late-Breaking Research & Clinical Trials
Chairs: Myla Goldman, <i>Virginia Commonwealth University</i> Amit Bar-Or, <i>University of Pennsylvania</i> <i>Presentations will be selected from late-breaking abstract submissions.</i>	
12:15 - 1:30 PM	Lunch
12:30 - 1:15 PM	Differential Diagnosis in Pediatric and Late Onset Multiple Sclerosis: An Update from the ACTRIMS Differential Diagnosis Consortium
12:30 – 12:42	Background and MS Mimics for LOMS Le Hua, <i>Cleveland Clinic</i>
12:42 – 12: 54	Mimics for POMS Cheryl Hemingway, <i>Great Ormond Street Hospital for Children (London)</i>
12:54 – 1:06	Future Directions and the Role of Imaging/Biomarkers Orhun Kantarci, <i>Mayo Clinic</i>
1:06 – 1:15	Q & A
1:30 - 3:00 PM	S6. Session 6 – Barriers in Clinical Trials
Theme: Effective clinical trial design including representation, outcome optimization, and participant selection. <i>Each speaker has 15 minutes and 25 minutes reserved for questions at the end.</i> Chairs: Francesca Bagnato, <i>Vanderbilt University</i> Annette Okai, <i>North Texas Institute of Neurology and Headache</i>	
1:30 - 1:35	Introduction
1:35 - 1:50	S6.1 Selecting Informative Patients for Phase 2 Progressive Trials in MS Marcus Koch, <i>University of Calgary</i>
1:50 - 2:05	S6.2 Ensuring Representation in Clinical Trials Mitzi Joi Williams, <i>Joi Life Wellness</i>
2:05 - 2:20	S6.3 Visual System as a Model for Neuroprotection Trials Shiv Saidha, <i>Johns Hopkins University</i>
2:20 - 2:35	S6.4 Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation María Inés Gaitán, <i>National Institutes of Health</i>

2:35 - 3:00	Q & A
3:00 - 3:15 PM	Awards Presentation & Closing